CSIMarket
 
Sarepta Therapeutics Inc   (SRPT)
Other Ticker:  
 
 
Price: $123.0500 $-0.71 -0.574%
Day's High: $125.245 Week Perf: 1.21 %
Day's Low: $ 121.60 30 Day Perf: -1.01 %
Volume (M): 1,246 52 Wk High: $ 159.89
Volume (M$): $ 153,283 52 Wk Avg: $115.21
Open: $123.49 52 Wk Low: $55.25



 Market Capitalization (Millions $) 10,938
 Shares Outstanding (Millions) 89
 Employees 1,400
 Revenues (TTM) (Millions $) 1,105
 Net Income (TTM) (Millions $) -691
 Cash Flow (TTM) (Millions $) -497
 Capital Exp. (TTM) (Millions $) 76

Sarepta Therapeutics Inc
Sarepta Therapeutics Inc is a biotechnology company that specializes in developing therapies for rare genetic diseases. The company is based in Cambridge, Massachusetts, and was founded in 1980.

Sarepta Therapeutics Inc focuses on developing and commercializing drugs for the treatment of Duchenne muscular dystrophy (DMD), a rare genetic disease that affects about 1 in every 3,500 males worldwide. The company's lead product candidate is a drug called eteplirsen, which is designed to treat DMD by repairing the genetic defects that cause the disease.

The company has a strong pipeline of other promising therapies, including drugs for the treatment of other types of muscular dystrophy and rare diseases such as limb-girdle muscular dystrophy, myotonic dystrophy, and spinal muscular atrophy.

Sarepta Therapeutics Inc has a robust research and development team made up of scientists, clinicians, and other experts with extensive experience in the field of genetic disease. The company has also built strong partnerships with academic institutions and other biotechnology companies, enabling it to access cutting-edge research and technology.

In addition to its drug development activities, Sarepta Therapeutics Inc is active in patient advocacy and education. The company works closely with patient advocacy groups and medical professionals to raise awareness about rare genetic diseases and to provide support to affected families. The company also sponsors research and educational programs, and provides financial assistance to families in need.

Sarepta Therapeutics Inc has a strong financial position, with a market capitalization of over $12 billion as of 2021, and a track record of revenue growth. The company has a broad investor base, including institutional investors, private equity firms, and individual investors.

Overall, Sarepta Therapeutics Inc is a successful biotechnology company that has made significant progress in developing therapies for rare genetic diseases. With its strong pipeline, experienced team, and commitment to patient advocacy, the company is well positioned for future growth and success.


   Company Address: 215 First Street Cambridge 2142 MA
   Company Phone Number: 274-4000   Stock Exchange / Ticker: NASDAQ SRPT
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

Sarepta Therapeutics Launches the 7th Annual Route 79 Duchenne Scholarship Program

Published Thu, Feb 29 2024 2:00 PM UTC

Sarepta Therapeutics, a leading precision genetic medicine company focused on rare diseases, has officially opened the annual Route 79 Duchenne Scholarship Program for the 2024-2025 academic year. This program aims to support and empower individuals living with Duchenne muscular dystrophy (DMD) and their siblings by awarding academic scholarships of up to $5,000. The applica...

Product Service News

Bidding Adieu to Beta Sarcoglycanopathy: The Promising Horizon of SRP-9003 in Phase 3, EMERGENE Clinical Trial

Published Tue, Jan 16 2024 2:02 PM UTC

Limb-girdle muscular dystrophy Type 2E (LGMD2E/R4) represents a genetic disorder wrought with human suffering. In particular, the lack of effective treatment options until now has only intensified the urgency for potential remedies. Amid such circumstances, a glimmer of hope emerges from Sarepta Therapeutics, Inc, the leading pioneer in precision genetic medicine for rare di...

Contract

Sarepta Surpasses Expectations: Stellar Revenue Growth and Stability Propel Precision Genetic Medicine Leader Forward

Published Mon, Jan 8 2024 4:55 PM UTC

Sarepta Therapeutics, a leading precision genetic medicine company specializing in rare diseases, has released its preliminaryn fourth quarter and full-year 2023 net product revenue and financial update at the 42nd Annual J.P. Morgan Healthcare Conference. This article will outline the key facts from the report and assess their impact on the company's future prospects.Key Fa...

Sarepta Therapeutics Inc

Sarepta Therapeutics Inc. Achieves Outstanding Revenue Growth, Emerges as Industry Leader in Q3 2023

Sarepta Therapeutics Inc, the major pharmaceutical preparations company, recently released its financial results for the third quarter of 2023. Despite industry peers experiencing top-line reductions, Sarepta showed significant growth in revenue, marking a defining moment for the company.
In the July to September 30 timeframe, Sarepta reported a revenue surge of 44.1%, reaching $331.82 million compared to the same quarter last year. This remarkable increase stands in stark contrast to the performance of other major pharmaceutical preparation companies. It is evident that Sarepta has managed to withstand the sector's momentum and emerge as a leader in the industry.

Stock Issue News

Sarepta Therapeutics Grants Equity Awards to Bolster Talent Acquisition and Retention

Published Tue, Oct 31 2023 11:02 PM UTC

Sarepta Therapeutics Grants Equity Awards as Material Inducement to Employment
Cambridge, Mass. - Sarepta Therapeutics Inc., a renowned pioneer in precision genetic medicine for rare diseases, recently announced the grant of equity awards to 12 individuals hired in October 2023. This decision was made under Sarepta's 2014 Employment Commencement Incentive Plan, upon appr...






 

Sarepta Therapeutics Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com